RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Predicting who will experience symptoms after Lyme disease remains challenging Each year, approximately 27,000 people are diagnosed with Lyme disease. For most, the symptoms disappear after treatment with antibiotics. Unfortunately, 25% of those treated have chronic symptoms, such as fatigue, concentration disorders or pain.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
Number of Lyme disease diagnoses remains high In 2021, the number of Lyme disease diagnoses with a red ring or rash– known as an erythema migrans, or EM – remained as high as in the previous survey in 2017. GPs diagnosed 25,600 patients with a red ring or rash caused by the Lyme bacteria.
More attention needed for potential impact of drug waste on drinking water quality Drug waste contains substances that are harmful to the quality of drinking water. Because this waste is dumped illegally, these substances can end up in sources of drinking water.
Start of invitations for the seasonal flu vaccination The invitation for the seasonal flu vaccination will land on your doormat this autumn. The flu vaccination protects people who are more likely to become ill or seriously ill from flu because of their age or medical condition.
Antibiotic use and antimicrobial resistance remain stable Antibiotic resistance in the Netherlands remained stable in 2021 compared with the five previous years. This is evident from the 2022 annual NethMap/MARAN report.
New test for Lyme disease is not reliable To determine whether someone has Lyme disease, doctors in the Netherlands often use antibody tests. For some time now, so-called cellular tests have been available on the market.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.